The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukemia and significantly increases the efficacy of nilotinib

Francis Joseph Giles

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukemia and significantly increases the efficacy of nilotinib

Francis Joseph Giles

Medicine

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

Original language	English (Ireland)
Journal	Journal Of Cellular And Molecular Medicine
Publication status	Published - 1 Jan 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Authors (Note for portal: view the doc link for the full list of authors)

Authors
Kelly, K., Swords, R., Mahalingam, D., Nawrocki, S., Padmanabhan, S., Giles, F., Carew, S

Cite this

@article{838829ad5b4841888a782b98f03f6e65,

title = "The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukemia and significantly increases the efficacy of nilotinib",

author = "Giles, \{Francis Joseph\}",

year = "2010",

month = jan,

day = "1",

language = "English (Ireland)",

journal = "Journal Of Cellular And Molecular Medicine",

}